Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 13/20 | 1.00 |
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 0.83 |
| ▸ | CASP3 | P42574 | 2/20 | 0.83 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.83 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.83 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.83 |
| ▸ | MMP2 | P08253 | 2/20 | 0.83 |
| ▸ | MMP9 | P14780 | 2/20 | 0.83 |
| ▸ | MMP8 | P22894 | 2/20 | 0.83 |
| ▸ | MMP13 | P45452 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.82 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.77 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31679090 | 1.00 | NPBWR1 (1.00) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL20982761 | 0.92 | NPC1 (0.97) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL5566191 | 0.91 | NPC1 (1.00) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL20982700 | 0.91 | NPC1 (0.94) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL31357765 | 0.90 | RAB9A (1.00) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL28761270 | 0.90 | RAB9A (1.00) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2308775 | 0.88 | NPBWR1 (0.79) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1171437 | 0.88 | NPC1 (0.82) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL3183544 | 0.86 | NPC1 (0.84) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL2247663 | 0.86 | NPBWR1 (1.00) | NPBWR1RAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | UNIVERSITY OF VIRGINIA | 2022-02-17 | — | — | US | disclosed |
| US-11090289-B2 | Compositions and methods for blocking sodium channels | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-08-17 | — | — | US | disclosed |
| US-11090289-B2 | Compositions and methods for blocking sodium channels | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-08-17 | — | — | US | disclosed |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | UNIVERSITY OF WASHINGTON (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017127627-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006076009-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
| EP-1558341-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1524974-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Paratek Pharmaceuticals, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004041209-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004001058-A2 | TRANSCRIPTION FACTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | PARATEK PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031649-A1 | COMPOUNDS FOR TREATMENT OF TRYPANOSOMES AND NEUROLOGICAL PATHOGENS AND USES THEREOF | TSPO, GBA1, NLN | NPBWR1 2746/4885RAB9A 829/4885MAPT 364/4885 |
| US-20060160799-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | NPBWR1 3544/4885RAB9A 4067/4885MAPT 4415/4885 |
| US-10399966-B2 | Compounds for treatment of trypanosomes and neurological pathogens and uses thereof | TSPO, GBA1, NLN | NPBWR1 2746/4885RAB9A 829/4885MAPT 364/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | NPBWR1 323/4885RAB9A 2198/4885MAPT 4542/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885RAB9A 3748/4885MAPT 3113/4885 |
| US-11090289-B2 | Compositions and methods for blocking sodium channels | SCN3A, SCN1B, SCN2B | NPBWR1 1227/4885RAB9A 2068/4885MAPT 183/4885 |
| US-20220047554-A1 | COMPOSITIONS AND METHODS FOR BLOCKING SODIUM CHANNELS | SCN3A, SCN1B, SCN2B | NPBWR1 1227/4885RAB9A 2068/4885MAPT 183/4885 |
| US-20030229065-A1 | Transcription factor modulating compounds and methods of use thereof | RELA, ATF4, JUN | NPBWR1 3736/4885RAB9A 4484/4885MAPT 4717/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885RAB9A 4325/4885MAPT 4858/4885 |
| US-20050124678-A1 | Transcription factor modulating compounds and methods of use thereof | JUN, CREBBP, TFEB | NPBWR1 3544/4885RAB9A 4067/4885MAPT 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.